approxim
patient
coronaviru
diseas
suffer
sever
diseas
like
pneumonia
becom
critic
ill
mortal
rate
among
suffer
critic
ill
report
nation
health
commiss
nation
administr
tradit
chines
medicin
peopl
republ
china
develop
clinic
guidelin
manag
nhcnatcmchina
guidelin
guidelin
chm
includ
part
treatment
plan
sever
recommend
develop
consensu
expert
thu
conduct
pilot
random
clinic
trial
rct
test
potenti
effect
guidelinebas
chm
treatment
sever
wuhan
china
openlabel
pilot
random
trial
sever
trial
approv
ethic
committe
dongzhimen
hospit
trial
regist
chines
clinic
trial
registri
trial
protocol
protocol
amend
provid
appendix
protocol
patient
screen
elig
gchamp
trial
upon
admiss
ongo
epidem
wuhan
china
patient
confirmatori
diagnosi
directli
admit
transfer
design
hospit
jan
chines
govern
design
hospit
treatment
wuhan
hubei
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
posit
test
result
polymerasechainreact
pcr
assay
respiratori
rate
rr
ratio
abl
provid
inform
consent
patient
exclud
known
life
expect
hour
less
home
oxygen
baselin
pregnant
lactat
diagnos
end
stage
diseas
use
immunosuppress
six
month
longer
elig
patient
provid
oral
inform
trial
given
opportun
ask
question
patient
will
take
part
trial
invit
interview
gather
necessari
inform
includ
verbal
consent
audio
interview
electron
record
elig
particip
random
ratio
chm
plu
standard
care
chm
plu
group
standard
care
alon
group
use
simpl
random
alloc
method
alloc
conceal
laboratori
personnel
outcom
assessor
per
nhcnatcmchina
guidelin
patient
receiv
standard
care
includ
hemodynam
monitor
laboratori
test
supplementari
oxygen
intraven
fluid
routin
pharmaceut
medic
medic
care
deem
appropri
onduti
physician
oral
ribavirinarbidol
remdesivir
part
standard
care
china
appendix
protocol
per
nhcnatcmchina
guidelin
patient
chm
plu
group
also
receiv
chm
within
hour
random
appendix
protocol
herbal
formula
support
jiangyin
tianjiang
pharmaceut
co
ltd
qualiti
herb
accord
chines
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
pharmacopoeia
herb
test
heavi
metal
microbi
contamin
residu
pesticid
ensur
meet
safeti
standard
china
prior
use
train
experienc
technician
prepar
decoct
formula
accord
standard
procedur
unit
formula
yield
decoct
divid
two
equal
portion
nurs
administ
decoct
patient
oral
via
feed
tube
need
twice
daili
total
seven
day
chm
plu
group
data
retriev
electron
medic
record
use
standard
case
record
form
creat
member
isar
intern
sever
acut
respiratori
emerg
infect
consortium
collabor
world
health
organ
primari
outcom
chang
diseas
sever
categori
treatment
sever
scale
score
hospit
discharg
meet
discharg
criteriadischarg
criteria
defin
normal
bodi
temperatur
day
significantli
improv
respiratori
symptom
oxygen
supplement
requir
stabl
normal
vital
sign
longer
day
lung
imag
show
obviou
absorpt
recsolut
acut
infiltr
neg
result
nucleic
acid
test
consecut
two
time
least
day
interv
test
score
mildimprov
andor
mild
clinic
symptom
pneumonia
chang
radiolog
imag
studi
score
moderateact
symptom
like
fever
respiratori
tract
symptom
pulmonari
infiltr
seen
imag
score
sever
meet
follow
respiratori
distress
rr
breathsmin
puls
oximetri
room
air
rest
state
arteri
partial
pressur
oxygen
oxygen
concentr
mmhg
score
critic
ill
meet
follow
mechan
ventil
shock
organ
failur
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
sinc
pilot
random
trial
sampl
size
calcul
perform
pharmaceut
intervent
minimum
sampl
size
per
group
usual
recommend
rule
thumb
pilot
studi
consid
dropout
rate
aim
recruit
total
sampl
size
patient
standard
care
group
chm
plu
group
compar
sever
ordin
logist
regress
shift
analysi
proport
patient
without
clinic
improv
treatment
assess
use
gener
linear
model
laboratori
find
perform
use
wilcoxon
ranksum
test
hodgeslehmann
estim
locat
shift
ci
present
outcom
assess
intentiontotreat
popul
imput
miss
data
statist
analys
perform
use
sa
version
sa
institut
inc
p
valu
less
consid
signific
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
fortytwo
screen
patient
includ
trial
appendix
figur
two
group
gener
well
balanc
baselin
although
older
women
enrol
chm
plu
group
standard
care
alon
group
tabl
gchamp
trial
support
measur
standard
care
similar
two
group
appendix
protocol
primari
outcom
one
patient
group
die
first
three
day
treatment
odd
shift
toward
death
lower
chm
plu
group
standard
care
group
tabl
best
knowledg
first
prospect
random
trial
investig
effect
nhcnatcmchina
guidelinebas
chm
patient
sever
trial
odd
shift
toward
death
critic
ill
day
treatment
lower
chm
plu
group
nonsignific
level
result
collabor
univers
normal
near
normal
leukocyt
differ
inflammatori
marker
retrospect
studi
data
patient
patient
admit
icu
underw
invas
mechan
ventil
die
wherea
composit
endpoint
occur
patient
sever
diseas
trial
patient
sever
requir
icu
care
die
within
day
diseas
sever
import
factor
consid
treatment
like
contribut
differ
two
studi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
ongo
trial
gilead
scienc
remdesivir
util
categori
ordin
scale
defin
primari
outcom
although
caus
viru
heal
without
treatment
major
patient
patient
gchamp
trial
receiv
antibiot
percentag
antibiot
use
compar
previou
studi
studi
sever
limit
includ
openlabel
design
small
sampl
size
addit
studi
lack
long
term
outcom
diseas
sever
scale
deserv
investig
despit
substanti
limit
gchamp
trial
provid
import
opportun
better
understand
chm
sever
first
time
gchamp
trial
provid
valuabl
inform
nation
guidelinebas
chm
treatment
hospit
patient
sever
effect
antivir
treatment
still
lack
continu
spread
outsid
china
potenti
effect
treatment
includ
chm
worth
vigor
investig
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
thank
intern
sever
acut
respiratori
emerg
infect
consortium
isar
share
data
collect
templat
publicli
websit
thank
patient
involv
studi
work
fund
project
dongzhimen
hospit
beij
univers
chines
medicin
tenthousand
talent
program
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
author
declar
compet
interest
addit
core
write
group
group
member
also
contribut
substant
conduct
gchamp
trial
author
contribut
equal
work
appendix
gchamp
collabor
group
author
dedic
larg
amount
time
studi
hope
improv
care
patient
outbreak
member
read
approv
final
report
author
agre
gchamp
group
member
submit
articl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
data
support
find
studi
avail
correspond
author
reason
request
particip
data
without
name
identifi
made
avail
approv
correspond
author
nation
health
commiss
public
studi
find
data
avail
other
request
research
team
provid
email
address
commun
data
approv
share
other
propos
detail
descript
studi
object
statist
analysi
plan
need
evalu
reason
request
data
correspond
author
nation
health
commiss
make
decis
base
materi
addit
materi
may
also
requir
process
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
chm
chines
herbal
medicin
data
present
median
iqr
unless
otherwis
indic
two
particip
standard
care
group
baselin
record
fever
chest
xray
ct
find
standard
care
plu
gc
standard
care
group
transfer
consid
new
admiss
trial
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
figur
denot
score
sever
scale
patient
chines
herbal
medicin
plu
standard
care
group
standard
care
alon
group
score
sever
scale
rang
differ
chines
herbal
medicin
plu
standard
care
group
standard
care
group
note
overal
distribut
score
favor
chines
herbal
medicin
plu
standard
care
group
common
odd
ratio
improv
point
confid
interv
ci
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
